LY 316108

Drug Profile

LY 316108

Alternative Names: NNC 112192

Latest Information Update: 09 Feb 2000

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly; Novo Nordisk
  • Class Analgesics; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Irritable bowel syndrome; Pain

Most Recent Events

  • 09 Feb 2000 No-Development-Reported for Irritable bowel syndrome in Denmark (PO)
  • 09 Feb 2000 No-Development-Reported for Irritable bowel syndrome in USA (PO)
  • 09 Feb 2000 No-Development-Reported for Pain in Denmark (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top